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Abstract 
Background: Neurocognitive deficits are reported to be high in HIV-1 positive patients, even 
with suppressive antiretroviral treatment and it has been suggested that HIV can cause 
accelerated or premature aging of the brain. In this study we measured hyperphosphorylated 
tau (p-tau) in CSF as a potential marker for premature CNS aging 
Methods: With a cross-sectional retrospective design, p-tau, total tau (t-tau), neopterin and 
HIV-RNA were measured in CSF together with plasma HIV-RNA and blood CD4+ T-cells of 
225HIV-infected patients below 50 years of age subdivided into three groups; untreated 
neuroasymptomatic (NA) (n=145), on suppressive antiretroviral treatment (cART) (n=49), 
and HIV-associated dementia (HAD) (n=31). HIV-negative healthy subjects served as 
controls (n=79). 

Results: P-tau was not significantly higher in any HIV-infected group compared to HIV-
negative controls. Significant increases in t-tau were as expected found in patients with HAD 
compared to NA, cART, and control groups (p<0.001 ).  
Conclusions: P-tau was not higher in HIV-infected compared to controls speaking against 
premature or accelerated aging of the brain in HIV. 
 
 
Introduction: 
 
HIV-infected patients are at increased risk for the premature development of 
age-associated comorbidities, such as cardiovascular disease, osteoporosis, non-AIDS 
associated malignancies and neurocognitive impairment. It has therefore been hypothesized 
that such individuals may be prone to accelerated aging. 
HIV-1 invades the brain at primary infection and is present in the CNS throughout the course 
of chronic infection. It is well established that HIV in the CNS can cause a chronic, 
smoldering neuroinflammation, with axonal degeneration and increased prevalence of 
declining cognitive functions as an effect[1, 2].  
In the pre-treatment years of the HIV pandemic, a common feature of late-stage AIDS was 
HIV-associated dementia (HAD), where up to 20% of patients developed severe cognitive 
and motor deficits[3, 4]. With combination antiretroviral treatment (cART), overt dementia is 
rare. However, studies indicate that still a large proportion of HIV-infected patients on cART 
exhibit milder cognitive disorders, divided into minor cognitive disorder (MND) and 
asymptomatic neurocognitive impairment (ANI)[5, 6]. Together with HAD, these conditions 
are summarized in the concept of HIV-associated neurocognitive disorders (HAND)[5]. 
Intrathecal immune activation is a general feature of HIV infection, and a persistent low-grade 

inflammation is often present also in antiretroviral treated patients despite several years of 
suppressed plasma viral loads[7, 8]. With an aging HIV-positive population on cART, there 
are rising concerns that the low-grade chronic inflammation caused by HIV in the CNS might 
lead to premature decline of neuronal capacity[9, 10].  Since the life expectancy is near to 
normal, differential diagnostics in regard to other types of dementia, mainly Alzheimer 
dementia (AD) will be important.  
A number of cerebrospinal fluid (CSF) biomarkers have been investigated as potential 
diagnostic tools in HIV, where neopterin and neurofilament light chain protein (NFL) are 
sensitive markers to assess intrathecal immune activation and neuronal damage 
respectively.[11-13]. NFL increases naturally with normal aging, but a significant increase in 
concentration is seen in both treated and untreated asymptomatic HIV-positive patients 
reflecting subclinical CNS injury[13]. In HAD, increased CSF NFL is a general feature. 
Another set of CSF biomarkers of interest in HIV is tau proteins and amyloid metabolites. 
These are used as one of the cornerstones in the clinical diagnose of AD, and it has been 
previously shown that the biomarker pattern of amyloid and tau differ in HAD compared to 
AD and HIV-negative controls[14, 15]. Total tau (t-tau) is a constituent of neurons in the 
CNS, facilitating microtubule stability and transport of organelles. Like NFL, increased CSF 
t-tau is a signal of neuronal injury, though less sensitive[14, 16]. In contrast, 
hyperphosphorylated tau (p-tau) is generally not increased in HIV-patients with neuronal 
injury and cognitive disease. Increased levels of t-tau reflect cortical axonal degenerations, 
whereas increased concentrations of p-tau in CSF indicate a pathological 
hyperphosphorylation of tau, where tau detaches from the microtubuli causing axonal 
instability[17]. Mouse-models suggest that inflammation might induce phosphorylation of 
tau, but the detailed characteristics of p-tau synthesis are not completely known[18, 19]. 
Increased concentrations of p-tau can be observed in the physiological aging process[20], but 
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large increases is a sign of pathological processes in the CNS, commonly referred to as 
tauopathies. The hallmark disease associated with increased p-tau is AD, where analysis of 
tau proteins in CSF is one of the cornerstones in clinical diagnosis.  
We hypothesize that if HIV is associated with premature or accelerated aging, p-tau could be 
expected to be higher in HIV-infected compared to controls of same age. We therefore 
assessed CSF p-tau in untreated and antiretrovirally treated HIV-infected patients without 
neurological disease below the age of 50, and compared to HIV-negative controls in the same 
ages. For comparison we also included patients with HAD. CSF t-tau and neopterin were 
analyzed to assess possible neural injury and intrathecal immune activation.  
 
Methods: 
 
Study design and subjects 
 
We used a retrospective, cross-sectional cohort design. Archived specimens of cerebrospinal 
fluid (CSF) and blood was collected between the years 1986-2014 from three academic 
centers; Sahlgrenska University hospital in Gothenburg, Sweden, San Francisco General 
Hospital, California, USA and San Raffaele Hospital, Milan, Italy. 225 HIV-1 positive 
patients, all under the age of 50 were included and subdivided into three groups; 
neuroasymptomatics without antiretroviral treatment (NA); n=145, neuroasymptomatics on 
suppressive antiretroviral treatment (cART) for at least 6 months; n=49 and HIV-associated 
dementia (HAD); n=31. 
The control group consisted of HIV-negative healthy volunteers; n=79. Subject characteristics 
are shown in table 1.  
Lumbar puncture was performed as part of the clinical routine on the HAD patients and under 
the auspices of clinical studies among the other subjects. Patients were defined as 
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neuroasymptomatic if no signs or symptoms of cognitive deficits were found at clinical 
examination or follow-ups. Neuropsychological testing was only performed on suspicion of 
neurocognitive decline. HAD was defined using the CDC and American Academy of 
Neurology Task Force Criteria using standard laboratory and clinical evaluations[5, 21, 22]. 
Suppressive cART was defined as <50 HIV-RNA copies/mL in consecutive blood-samples 
for at least 6 months. All subjects were studied under research protocols approved by the 
institutional review boards at each center and followed the guidelines of the Helsinki 
declaration. All patients received written and verbal study information. Informed consent was 
obtained and documented in their respective patient file. 
Analytical methods 
 
CSF samples were submitted to low-speed centrifugation to remove cells, aliquoted, and 
frozen to − 70 °C within 1 hour of performing the lumbar puncture for storage until analysis.  
CSF p-tau, and t-tau were measured using enzyme linked immunosorbent assay (ELISA) as 
described in previous publications[23, 24]. 
Neopterin was analyzed in CSF using a commercially available immunoassay (BRAHMS, 
Berlin, Germany) with an upper normal reference value of 5.8 nmol/L[11].  
HIV RNA in CSF and plasma were measured using the Roche Amplicor Monitor version 1.5, 
Roche Taqman assay version 1 or 2 (Hoffman La-Roche, Basel, Switzerland) or Abbott 
RealTime HIV-1 assay (Abbott Laboratories. Abbott Park, Illinois, U.S.A.). Other 
measurements, including blood CD4+ T-cell counts, CSF WBC and CSF:blood albumin ratio, 
were performed in the local clinical laboratories at each study site. 
 
Statistical analysis 
 

Continuous variables were log10 transformed where appropriate for the tests used. 
ANOVA with Tukey’s multiple comparisons post hoc test was used to assess differences 
between multiple groups. A general linear model was used when comparing tau protein to 
age. Pearson correlation was used to establish dependency between neopterin, HIV-RNA and 
tau proteins.   
In cases of p- and t-tau levels below the detection limit, we used the lower reference divided 
by two in calculations (for p-tau 8 (<15) ng/l, for t-tau 36 (<72) ng/l). 
General descriptive statistics are presented as median and interquartile range (IQR). All 
statistical analyses were performed using IBM SPSS Statistics© version 20 or Prism© version 
5 (Graphpad Software Inc, La Jolla, CA). 
 
Results 
P-tau was not significantly higher in any HIV-infected group compared to HIV-negative 
controls. In contrary, p-tau was lower in the cART group compared to controls (p<0.05), but 
not when comparing to the NA and HAD groups. No significant differences were seen when 
comparing the other groups (Fig 1a and table 2). When looking at a general linear model 
assessing dependency between p-tau and age, no significant differences in slopes or levels 
were found between groups.   
The HAD group exhibited clear increases in t-tau compared to all other groups (p <0.001 for 
all). Both NA and cART groups had somewhat lower concentrations of t-tau compared to 
controls (p = 0.01 and p < 0.01 respectively) (table 2 and fig 1b). 
T-tau was significantly correlated with CSF neopterin (p < 0.001, r = 0.24) and CSF HIV-
RNA (p < 0.05, r = 0.16). No such correlations were found for p-tau but a relatively strong 
correlation was found between t- and p-tau (p < 0.0001, r = 0.55). 

The ratio of P-tau to T-tau was significantly decreased in HAD compared to all other groups 
(p<0.001) (table 2 and Fig 1c).  
 
Discussion 
HIV-infected patients are at increased risk for developing neurocognitive disorders, likely due 
to a complex chronic inflammatory response to the virus in CNS[7, 25]. Discrete 
neurocognitive impairments (ANI and MND) persist even with widespread access to 
suppressive cART[6] and it has been speculated that accelerated or premature CNS aging may 
be part of the pathogenesis of neurocognitive decline in HIV, mainly in untreated, but also in 
patients with suppressive cART.  
  
To the best of our knowledge, this is the first study using CSF p-tau as a potential marker for 
brain aging in HIV. We found no support for premature CNS aging in HIV-infected patients 
as measured by CSF p-tau concentrations. HIV-patients did not exhibit elevated levels of p-
tau compared to HIV-negative controls. There were no differences in p-tau levels between 
HAD, characterized by  severe neurocognitive decline and neuronal injury, 
neuroasymptomatic HIV-infected untreated patients and patients on suppressive cART. 
Neither was any difference in p-tau elevations or slope found between groups when the 
relation of p-tau and age was assessed with a general linear model. Thus, we found no support 
for the hypothesis of premature brain aging in HIV by p-tau analyses. 
Patients on cART had somewhat lower levels of p-tau compared to controls. When looking at 
p-tau/t-tau ratio, this difference disappeared, suggesting that this finding may have been 
coincidental.  
In accordance with previous studies t-tau was largely increased in HAD, most likely reflecting 
prominent neuroinflammation and axonal damage, but no increase was seen in the 
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neuroasymptomatic groups with and without treatment [14, 15, 26]. Contradicting results 
regarding p-tau in HAD have previously been presented, some have claimed that p-tau is 
increased in HAD[15, 27] while other have not found such association[14, 16]. In this study, 
no increase in p-tau was noted in HAD and the p/t-tau ratio was accordingly significantly 
lower in HAD compared to the other groups.  
There are several limitations to our study. First, the sample size might be too low to detect 
small differences between groups. Second, the study was restricted to subjects below the age 
of 50 years and an incipient difference in older ages could not be ruled out. Third, although all 
patients were analyzed for p-tau and t-tau with the same commercial method, there could 
theoretically be inter-batch variations that influence the results since all samples were not 
analyzed at the same time points. Fourth, and maybe most important, this was a cross-
sectional study. Ideally, a longitudinal study following patients and controls for a long period 
of time would have been ideal, but difficult to achieve. 
In summary, it is debated and controversial if premature brain aging is a real feature of HIV. 
We did not find any evidence for this in our present study. However, p-tau may be an 
unreliable marker of CNS aging and the possibility of premature or accelerated CNS aging in 
HIV could not be precluded by this study.  
 
 
 
 
 
 
 
 

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Table 1. Background characteristics 
Group  N Gender Age Plasma HIV 
RNA (log10) 
CSF HIV 
RNA (log10) 
   Female 
(n) 
Male 
(n) 
Median years 
(IQR) 
Median copies/mL 
(IQR) 
HIV+ NA  145 37 108 36 (31-42) 4.76 (4.23-5.34) 3.64 (2.39-
4.37) 
HIV+ 
HAD 
 31 5 26 37 (33-44) 5.15(4.49-
5.63)* 
5.12 (3.95-
5.41)** 
HIV+ 
cART 
 
 
49 15 34 38 (32-43) 0 (0-1.67) 0 (0-1.69) 
HIV- 
control 
 
 
79 27 52 39 (31-44) N/A N/A 
  
N/A: Not available 
*5 patients missing 
**2 patients missing 
 
 
 
 
 
 
 
 
 

 
Table 2. Summary of biomarker concentrations across groups 
Group  
P-tau 
(ng/l) 
Median (IQR) 
T-tau 
(ng/l) 
Median (IQR) 
P-tau/T-tau ratio 
(ng/l) 
Median (IQR) 
CSF Neopterin 
(nmol/L) 
(Median (IQR) 
HIV+ NA  35 (26-45) 138 (103.8-207)* 0.25 (0.17-0.33)* 17.1 (10.8-28.6)** 
HIV+ HAD  30.5 (23.8-42)* 404 (273-690) 0.075 (0.04-0.11) 50.5 (26.3-78.6)*** 
HIV+ cART  31 (23-37) 132 (97-187.8)** 0.26 (0.17-0.31)** 5.2 (4.2-6.9)* 
HIV- control  37 (28.3-49) 181.4 (124.2-265.7) 0.2 (0.17-0.23) N/A 
N/A = Not available 
* = 1 Patient missing 
** = 5 patients missing 
*** = 3 patients missing

 
Legends to figures 
 
Fig 1a: P-tau (y-axis) across group. Log10 transformed. P-tau was significantly lower 
(p<0.05) in cART compared to controls. No other significant differences were noted 
 
Fig 1b: T-tau (y-axis) across group. Log10 transformed. T-tau was significantly higher in 
HAD compared to all other groups (p<0.001). cART and NA was significantly lower 
compared to controls (p<0.004 and p<0.01 respectively) 
 
Fig 1c: P-tau/t-tau ratio (y-axis) across group. Log10 transformed. P-tau/T-tau ratio was 
significantly lower in HAD compared to all other groups (p<0.001). No significant 
differences were seen between other groups 
 
.  
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